Background: CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a rare subtype of DLBCL with invasive clinical features and poor prognosis. Current clinical variables based on prognostic systems for DLBCL are inadequate to accurately stratify the prognosis of CD5+ DLBCL.
Methods: A total of 195 CD5+ DLBCL patients were retrospectively recruited from nine centers in Huaihai Lymphoma Working Group. MaxStat analysis was used to identify optimal cutoff points for continuous variables; univariable and multivariable Cox analyses were used for variable selection; Kaplan-Meier curve was used to analyze the value of variables on prognosis; and C-index, Brier score, and decision curve analysis were measured for predicting model performance.
Results: The derivation and validation cohorts consisted of 131 and 64 patients. Of the whole cohort, median age at diagnosis was 61 years, of whom 100 (51.28%) were males and the 5-year overall survival rate was 42.1%. MYC, BCL-2, and the coexpression of MYC/BCL-2 could distinguish the survival of CD5+ DLBCL. Multivariable analysis showed that age, IPI, red blood cell count, neutrophil count, MYC expression, and hepatosplenomegaly were independent predictors, and the prognostic nomogram was developed. The C-index of the nomogram was 0.809 in the derivation and 0.770 in the validation cohort. Decision curve analysis proved that compared with IPI, the specific nomogram showed a better identification in CD5+ DLBCL.
Conclusion: The proposed nomogram provided a valuable tool for prognosis prediction in patients with CD5+ DLBCL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595286 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.754180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation.
Pathol Int
December 2024
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
CD5 expression is seen in 5%-10% of de novo diffuse large B-cell lymphomas (DLBCLs). Primary large B-cell lymphoma of the central nervous system (PCNS-LBCL) also exhibits CD5 expression in a minority of cases, however, clinicopathological and molecular features remain largely unclarified. Here we present the clinical, molecular, and pathological features of 11 CD5-positive () PCNS-LBCL cases, occupying 6.
View Article and Find Full Text PDFErythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report.
Case Rep Oncol
September 2024
Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Introduction: Erythema nodosum (EN) is the most common form of panniculitis. EN can be idiopathic or secondary to an underlying systemic disease, infection, drug use, or tumor. CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a relapsed and refractory lymphoma, and further understanding of its pathology is required.
View Article and Find Full Text PDFTonsillar Diffuse Large B-Cell Lymphoma of Non-Germinal Center Type With Cluster of Differentiation 5 Positive in a Pediatric Girl.
J Med Cases
November 2024
Collage of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Lymphoma is a common malignancy in children. It is the second most common malignancy in children older than 1 year of age. Most extranodal non-Hodgkin lymphoma (NHL) in the head and neck is usually caused by diffuse large B-cell lymphoma (DLBCL), but pediatric DLBCL with cluster of differentiation (CD)5 expression is rarely discussed in the literature.
View Article and Find Full Text PDFRecent advances in CD5 diffuse large B-cell lymphoma.
Ann Hematol
November 2024
Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma, with a rare subset known as CD5 DLBCL, affecting about 5-10% of patients and often presenting in older females with more severe disease symptoms.
- CD5 DLBCL patients tend to have poorer prognostic factors, such as higher levels of lactate dehydrogenase and advanced disease with increased risks of central nervous system relapse and bone marrow involvement.
- Traditional treatments like R-CHOP are less effective for CD5 DLBCL, prompting interest in newer therapies, including BTK inhibitors and immunotherapy, though further research is needed to ascertain the best treatment approaches.
[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5 Diffuse Large B-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
Article Synopsis
- The study focused on a patient with relapsed CD5 diffuse large B-cell lymphoma (DLBCL), analyzing their clinical features and treatment results.
- After initially achieving complete remission with R-ECHOP chemotherapy, the patient relapsed but responded well to a combination of PD-1 inhibitors and lenalidomide, leading to another complete remission and reduced IL-10 levels.
- These findings suggest that the PD-1 inhibitor plus lenalidomide could be a promising new therapy for patients with relapsed CD5 DLBCL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!